Yongin, South Korea

Hye Jeong Shin

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Autophagysciences Inc.. Active years: 2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hye Jeong Shin. Retrieved from https://idiyas.com/inventor/hye-jeong-shin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0


Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hye Jeong Shin: Innovator in Autophagy Research

Introduction

Hye Jeong Shin is a notable inventor based in Yongin-si, South Korea. She has made significant contributions to the field of pharmaceutical sciences, particularly in the area of autophagy regulation. Her work focuses on developing novel compounds that can be utilized in treating various diseases.

Latest Patents

Hye Jeong Shin holds a patent for a compound and pharmaceutical composition that comprises the same. This patent, titled "Compound and pharmaceutical composition comprising same," describes a novel compound that activates autophagy. The implications of her research are profound, as it can be valuable in preventing or treating diseases associated with autophagy regulation. She has 1 patent to her name.

Career Highlights

Hye Jeong Shin is currently associated with Autophagy Sciences Inc., where she continues her research and development efforts. Her innovative approach to pharmaceutical compositions has positioned her as a key figure in her field.

Collaborations

Hye Jeong Shin collaborates with esteemed colleagues, including Jung Ju Kim and Seong-Won Song. These partnerships enhance her research capabilities and contribute to the advancement of autophagy-related therapies.

Conclusion

Hye Jeong Shin's work in autophagy research exemplifies the impact of innovative thinking in the pharmaceutical industry. Her contributions are paving the way for new treatments that could significantly improve patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…